Previous studies have demonstrated that treatment with the mitochondrial fusion protein mitofusin-2 improves mitochondrial function and reduces hepatic steatosis in mouse models of NAFLD [7]. The gene discussed is MFN2; the disease is metabolic dysfunction-associated steatotic liver disease.